# Joint ECDC-WHO Regional Office for Europe Mpox Surveillance Bulletin

11 August 2023

## Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>SURVEILLANCE SUMMARY</td>
<td>1</td>
</tr>
<tr>
<td>INTRODUCTION</td>
<td>2</td>
</tr>
<tr>
<td>PURPOSE AND SCOPE</td>
<td>2</td>
</tr>
<tr>
<td>CASE DEFINITION (WHO and ECDC)</td>
<td>3</td>
</tr>
<tr>
<td>KEY INDICATORS</td>
<td>6</td>
</tr>
<tr>
<td>IHR SUMMARY</td>
<td>6</td>
</tr>
<tr>
<td>MAPS</td>
<td>8</td>
</tr>
<tr>
<td>EPICURVES</td>
<td>11</td>
</tr>
<tr>
<td>SUMMARY TABLE</td>
<td>21</td>
</tr>
<tr>
<td>DEMOGRAPHICS</td>
<td>22</td>
</tr>
<tr>
<td>CLINICAL DESCRIPTION</td>
<td>23</td>
</tr>
<tr>
<td>OUTCOME, HIV STATUS</td>
<td>25</td>
</tr>
<tr>
<td>SEXUAL ORIENTATION</td>
<td>26</td>
</tr>
<tr>
<td>MICROBIOLOGICAL ANALYSES</td>
<td>27</td>
</tr>
<tr>
<td>DISCLAIMERS AND ACKNOWLEDGMENTS</td>
<td>30</td>
</tr>
<tr>
<td>COPYRIGHT STATEMENT AND DISCLAIMERS</td>
<td>30</td>
</tr>
<tr>
<td>ACKNOWLEDGMENTS</td>
<td>31</td>
</tr>
<tr>
<td>ANNEX</td>
<td>32</td>
</tr>
</tbody>
</table>
SURVEILLANCE SUMMARY

A total of 26,001 cases of mpox (formerly named monkeypox) have been identified through IHR mechanisms, official public sources and TESSy up to 10 August 2023, 14:00, from 45 countries and areas throughout the European Region. **Over the past 4 weeks, 65 cases of mpox have been identified from 8 countries and areas.**

Case-based data were reported for 25,893 cases from 41 countries and areas to ECDC and the WHO Regional Office for Europe through The European Surveillance System (TESSy), up to 10 August 2023, 10:00.

Of the 25,893 cases reported in TESSy, 25,714 were laboratory confirmed. Furthermore, where sequencing was available, 487 were confirmed to belong to Clade II, formerly known as the West African clade. The earliest known case has a specimen date of 07 March 2022 and was identified through retrospective testing of a residual sample. The earliest date of symptom onset was reported as 17 April 2022.

The majority of cases were between 31 and 40 years-old (10,189/25,861 - 39%) and male (25,396/25,830 - 98%). Of the 11,315 male cases with known sexual orientation, 96% self-identified as men who have sex with men. Among cases with known HIV status, 38% (4,076/10,729) were HIV-positive. The majority of cases presented with a rash (15,415/16,140 - 96%) and systemic symptoms such as fever, fatigue, muscle pain, chills, or headache (10,968/16,140 - 68%). There were 825 cases hospitalised (7%), of which 277 cases required clinical care. Eight cases were admitted to ICU, and seven cases of mpox were reported to have died.

To date, WHO and ECDC have been informed of five cases of occupational exposure. In four cases of occupational exposure, health workers were wearing recommended personal protective equipment but were exposed to body fluid while collecting samples. The fifth case was not wearing personal protective equipment. The WHO interim guidance on clinical management and infection prevention and control for mpox remains valid and is available at [https://apps.who.int/iris/handle/10665/355798](https://apps.who.int/iris/handle/10665/355798).
INTRODUCTION

PURPOSE AND SCOPE

This report provides an overview of the total number of cases of mpox (formerly named monkeypox) identified by ECDC and the WHO Regional Office for Europe through IHR mechanisms and official public sources and case-based data through The European Surveillance System (TESSy) up to 10 August 2023.

The first summary table and maps (first two tabs) describe the number of cases identified through the different platforms. The following figures and tables describe national case-based data for surveillance of mpox reported in TESSy from all the countries and areas of the WHO European Region, including the 27 countries of the European Union (EU) and the additional three countries of the European Economic Area (EEA).

Case Report Form Data are submitted through the case-based record type mpox (MPX) to The European Surveillance System (TESSy) database hosted at ECDC.
CASE DEFINITION (WHO and ECDC)

As of 22 December 2022

Cases of mpox should be reported to TESSy if they meet any of the WHO, ECDC or national case definitions.

Confirmed case

- A person with laboratory confirmed MPXV infection by detection of unique sequences of viral DNA by real-time polymerase chain reaction (PCR)\(^1\) and/or sequencing.

Probable case:

- A person presenting with an unexplained acute skin rash, mucosal lesions or lymphadenopathy (swollen lymph nodes). The skin rash may include single or multiple lesions in the ano-genital region or elsewhere on the body. Mucosal lesions may include single or multiple oral, conjunctival, urethral, penile, vaginal, or ano-rectal lesions. Ano-rectal lesions can also manifest as ano-rectal inflammation (proctitis), pain and/or bleeding.

AND One or more of the following:

- has an epidemiological link\(^2\) to a probable or confirmed case of mpox in the 21 days before symptom onset;
- identifies as gay, bisexual or other cis or trans man who has sex with men;
- has had multiple and/or casual sexual partners in the 21 days before symptom onset;
- has detectable levels of anti-orthopoxvirus (OPXV) IgM antibody\(^3\) (during the period of 4 to 56 days after rash onset); or a four-fold rise in IgG antibody titer based on acute (up to day 5-7) and convalescent (day 21 onwards) samples; in the absence of a recent smallpox/mpox vaccination or other known exposure to OPXV;
- has a positive test result for orthopoxviral infection (e.g., OPXV-specific PCR without MPXV-specific PCR or sequencing)\(^1\).

Suspected case

- A person who is a contact of a probable or confirmed mpox case in the 21 days before the onset of signs or symptoms, and who presents with any of the following: acute onset of fever (>38.5°C), headache, myalgia (muscle pain/body aches), back pain, profound weakness or fatigue.
• A person presenting since 01 January 2022 with an unexplained acute skin rash, mucosal lesions or lymphadenopathy (swollen lymph nodes). The skin rash may include single or multiple lesions in the ano-genital region or elsewhere on the body. Mucosal lesions may include single or multiple oral, conjunctival, urethral, penile, vaginal, or ano-rectal lesions. Ano-rectal lesions can also manifest as ano-rectal inflammation (proctitis), pain and/or bleeding.

**AND for which the following common causes of acute rash or skin lesions do not fully explain the clinical picture:**

• varicella zoster, herpes zoster, measles, herpes simplex, bacterial skin infections, disseminated gonococcus infection, primary or secondary syphilis, chancroid, lymphogranuloma venereum, granuloma inguinale, molluscum contagiosum, allergic reaction (e.g., to plants); and any other locally relevant common causes of papular or vesicular rash.

**N.B. It is not necessary to obtain negative laboratory results for listed common causes of rash illness in order to classify a case as suspected. Further, if suspicion of mpox or MPXV infection is high due to either history and/or clinical presentation or possible exposure to a case, the identification of an alternate pathogen which causes rash illness should not preclude testing for MPXV, as co-infections have been identified.**

**Discarded case**

• A suspected or probable case for which laboratory testing of lesion fluid, skin specimens or crusts by PCR and/or sequencing is negative for MPXV\(^1\).
• Conversely, a retrospectively detected probable case for which lesion testing can no longer be adequately performed (i.e., after the crusts fall off) and no other specimen is found PCR-positive, would remain classified as a probable case.
• A suspected or probable case should not be discarded based on a negative result from an oropharyngeal, anal or rectal swab or from a blood test alone.

The previous WHO and ECDC case definitions can be found in the Annex.

1. PCR on a blood specimen may be unreliable and should also not be used alone as a first line diagnostic test. If blood PCR is negative and was the only test done, this is not sufficient to discard a case that otherwise meets the definition of a suspected for probable case. This applies regardless of whether the blood PCR was for OPXV or MPXV specific.
2. The person has been exposed to a probable or confirmed monkeypox case.

3. Serology can be used for retrospective case classification for a probable case in specific circumstances such as when diagnostic testing through PCR of skin lesion specimens has not been possible, or in the context of research with standardized data collection. The primary diagnostic test for monkeypox diagnosis is PCR of skin lesion material or other specimen such as an oral or nasopharyngeal swab as appropriate. Serology should not be used as a first line diagnostic test.
KEY INDICATORS

IHR SUMMARY

Table 1: Summary of number of cases of mpox identified through IHR mechanisms and official public sources and reported to TESSy, European Region, 2022–2023

Countries and areas reporting new cases in the past 4 ISO weeks are highlighted in blue
<table>
<thead>
<tr>
<th>Country/Area</th>
<th>Number of new cases identified through IHR, official public sources and TESSy in the past 4 ISO weeks</th>
<th>Cumulative number of cases identified through IHR, official public sources and TESSy</th>
<th>Cumulative number of cases reported through TESSy</th>
<th>Cond</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spain</td>
<td>6</td>
<td>7565</td>
<td>7565</td>
<td>1</td>
</tr>
<tr>
<td>France</td>
<td>3</td>
<td>4150</td>
<td>4150</td>
<td>1</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>10</td>
<td>3771</td>
<td>3722</td>
<td>1</td>
</tr>
<tr>
<td>Germany</td>
<td>3</td>
<td>3694</td>
<td>3676</td>
<td>1</td>
</tr>
<tr>
<td>Netherlands(Kingdom of the)</td>
<td>1</td>
<td>1266</td>
<td>1266</td>
<td>1</td>
</tr>
<tr>
<td>Portugal</td>
<td>40</td>
<td>1005</td>
<td>1005</td>
<td>1</td>
</tr>
<tr>
<td>Italy</td>
<td>1</td>
<td>958</td>
<td>958</td>
<td>1</td>
</tr>
<tr>
<td>Belgium</td>
<td>0</td>
<td>795</td>
<td>795</td>
<td>0</td>
</tr>
<tr>
<td>Switzerland</td>
<td>0</td>
<td>554</td>
<td>554</td>
<td>0</td>
</tr>
<tr>
<td>Austria</td>
<td>0</td>
<td>328</td>
<td>328</td>
<td>0</td>
</tr>
<tr>
<td>Israel</td>
<td>0</td>
<td>263</td>
<td>233</td>
<td>0</td>
</tr>
<tr>
<td>Sweden</td>
<td>0</td>
<td>260</td>
<td>260</td>
<td>0</td>
</tr>
<tr>
<td>Ireland</td>
<td>0</td>
<td>229</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Poland</td>
<td>0</td>
<td>217</td>
<td>217</td>
<td>0</td>
</tr>
<tr>
<td>Denmark</td>
<td>0</td>
<td>196</td>
<td>196</td>
<td>0</td>
</tr>
<tr>
<td>Norway</td>
<td>0</td>
<td>96</td>
<td>96</td>
<td>0</td>
</tr>
<tr>
<td>Greece</td>
<td>0</td>
<td>88</td>
<td>88</td>
<td>0</td>
</tr>
<tr>
<td>Hungary</td>
<td>0</td>
<td>80</td>
<td>80</td>
<td>0</td>
</tr>
<tr>
<td>Czeckia</td>
<td>0</td>
<td>71</td>
<td>71</td>
<td>0</td>
</tr>
<tr>
<td>Luxembourg</td>
<td>1</td>
<td>58</td>
<td>58</td>
<td>1</td>
</tr>
<tr>
<td>Slovenia</td>
<td>0</td>
<td>47</td>
<td>47</td>
<td>0</td>
</tr>
<tr>
<td>Romania</td>
<td>0</td>
<td>47</td>
<td>47</td>
<td>0</td>
</tr>
<tr>
<td>Finland</td>
<td>0</td>
<td>42</td>
<td>42</td>
<td>0</td>
</tr>
<tr>
<td>Serbia</td>
<td>0</td>
<td>40</td>
<td>40</td>
<td>0</td>
</tr>
<tr>
<td>Malta</td>
<td>0</td>
<td>34</td>
<td>34</td>
<td>0</td>
</tr>
<tr>
<td>Croatia</td>
<td>0</td>
<td>33</td>
<td>33</td>
<td>0</td>
</tr>
<tr>
<td>Iceland</td>
<td>0</td>
<td>16</td>
<td>16</td>
<td>0</td>
</tr>
<tr>
<td>Slovakia</td>
<td>0</td>
<td>14</td>
<td>14</td>
<td>0</td>
</tr>
<tr>
<td>Türkiye</td>
<td>0</td>
<td>12</td>
<td>12</td>
<td>0</td>
</tr>
<tr>
<td>Estonia</td>
<td>0</td>
<td>11</td>
<td>11</td>
<td>0</td>
</tr>
<tr>
<td>Bosnia and Herzegovina</td>
<td>0</td>
<td>9</td>
<td>9</td>
<td>0</td>
</tr>
<tr>
<td>Gibraltar</td>
<td>0</td>
<td>6</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>Bulgaria</td>
<td>0</td>
<td>6</td>
<td>6</td>
<td>0</td>
</tr>
<tr>
<td>Latvia</td>
<td>0</td>
<td>6</td>
<td>6</td>
<td>0</td>
</tr>
<tr>
<td>Cyprus</td>
<td>0</td>
<td>5</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>Lithuania</td>
<td>0</td>
<td>5</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>Ukraine</td>
<td>0</td>
<td>5</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>Andorra</td>
<td>0</td>
<td>4</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>Montenegro</td>
<td>0</td>
<td>3</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Monaco</td>
<td>0</td>
<td>3</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Georgia</td>
<td>0</td>
<td>2</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Russian Federation</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Republic of Moldova</td>
<td>0</td>
<td>2</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Greenland</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>San Marino</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>65</strong></td>
<td><strong>26001</strong></td>
<td><strong>25893</strong></td>
<td><strong>0</strong></td>
</tr>
</tbody>
</table>
MAPS

ECDC Map

Map Figure 1a: Distribution of new cases of mpox reported in the past 4 ISO weeks, European Region, TESSy, 2022–2023, ECDC borders
Map Figure 1b: Distribution of all cases of mpox, European Region, TESSy, 2022–2023, ECDC borders

Geographical distribution of cumulative confirmed mpox cases per 1 000 000 population in the EU/EEA, Western Balkans and Türkiye, as of 10 Aug 2023

- ≥100 cases per 1 000 000
- 50-99 cases per 1 000 000
- 10-49 cases per 1 000 000
- < 10 cases per 1 000 000
- No reported cases
- Not included

Countries not visible in the main map extent
- Malta
- Liechtenstein

The boundaries and names shown on this map do not imply official endorsement or acceptance by the European Union. ECDC. Map produced on 10 Aug 2023.
Map Figure 1c: Distribution of cases of mpox, European Region, TESSy, 2022–2023

Monkeysxox total cumulative incidence and cases newly reported in the last 4 weeks
as of 10 August 2023 16:30 CET

The designations employed and the presentation of the material do not imply the expression of any opinion whatsoever on the part of the Decedent of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Determined and dashed lines as major expressed apprehensions locations for which there may not yet full information.

Data source: WHO European Region TESSy Database
Contact person: graham.brown@who.int
© World Health Organization
**EPICURVES**

*Date of notification is defined as the date when the case report is notified for the first time to the place of notification, date of diagnosis is defined as the first date of clinical or laboratory diagnosis, and date of onset as the date of onset of any symptoms.*

**Overall by date of notification**

**Figure 2: Overall number of cases of mpox, per date of notification, European Region, TESSy, 2022–2023**
Overall by date of symptom onset

Figure 3: Overall number of cases of mpox, per date of symptom onset, European Region, TESSy, 2022–2023
By date of onset and by country or area

**Figure 4: Number of cases of mpox, per ISO week and per country/area of notification, European Region, TESSy, 2022–2023**

Andorra  Estonia  Ireland  Poland  Sweden
Austria  Finland  Israel  Portugal  Switzerland
Belgium  France  Italy  Republic of Moldova  Türkiye
Bosnia and Herzegovina  Georgia  Latvia  Romania  Ukraine
Bulgaria  Germany  Lithuania  Serbia  United Kingdom
Croatia  Gibraltar  Luxembourg  Slovakia
Cyprus  Greece  Malta  Slovenia
Czechia  Hungary  Netherlands (Kingdom of the)  Spain
Denmark  Iceland  Norway
By date of onset and by country or area - country/area level

Figure 5: Number of cases of mpox, per ISO week and per country/area of notification, European Region, TESSy, 2022–2023
*Week of symptom onset or earliest of week of diagnosis or notification if missing*
## SUMMARY TABLE

Table 2: Summary of number of probable and confirmed cases of mpox as well as deaths, by reporting country/area, European Region, TESSy, 2022–2023

<table>
<thead>
<tr>
<th>Country</th>
<th>Confirmed cases</th>
<th>Probable cases</th>
<th>Total cases</th>
<th>Total deaths</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andorra</td>
<td>4</td>
<td>0</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>Austria</td>
<td>328</td>
<td>0</td>
<td>328</td>
<td>0</td>
</tr>
<tr>
<td>Belgium</td>
<td>795</td>
<td>0</td>
<td>795</td>
<td>2</td>
</tr>
<tr>
<td>Bosnia and Herzegovina</td>
<td>9</td>
<td>0</td>
<td>9</td>
<td>0</td>
</tr>
<tr>
<td>Bulgaria</td>
<td>6</td>
<td>0</td>
<td>6</td>
<td>0</td>
</tr>
<tr>
<td>Croatia</td>
<td>33</td>
<td>0</td>
<td>33</td>
<td>0</td>
</tr>
<tr>
<td>Cyprus</td>
<td>5</td>
<td>0</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>Czechia</td>
<td>71</td>
<td>0</td>
<td>71</td>
<td>1</td>
</tr>
<tr>
<td>Denmark</td>
<td>196</td>
<td>0</td>
<td>196</td>
<td>0</td>
</tr>
<tr>
<td>Estonia</td>
<td>11</td>
<td>0</td>
<td>11</td>
<td>0</td>
</tr>
<tr>
<td>Finland</td>
<td>42</td>
<td>0</td>
<td>42</td>
<td>0</td>
</tr>
<tr>
<td>France</td>
<td>4150</td>
<td>0</td>
<td>4150</td>
<td>0</td>
</tr>
<tr>
<td>Georgia</td>
<td>2</td>
<td>0</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Germany</td>
<td>3676</td>
<td>0</td>
<td>3676</td>
<td>0</td>
</tr>
<tr>
<td>Gibraltar</td>
<td>5</td>
<td>0</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>Greece</td>
<td>88</td>
<td>0</td>
<td>88</td>
<td>0</td>
</tr>
<tr>
<td>Hungary</td>
<td>80</td>
<td>0</td>
<td>80</td>
<td>0</td>
</tr>
<tr>
<td>Iceland</td>
<td>16</td>
<td>0</td>
<td>16</td>
<td>0</td>
</tr>
<tr>
<td>Ireland</td>
<td>229</td>
<td>0</td>
<td>229</td>
<td>0</td>
</tr>
<tr>
<td>Israel</td>
<td>233</td>
<td>0</td>
<td>233</td>
<td>0</td>
</tr>
<tr>
<td>Italy</td>
<td>958</td>
<td>0</td>
<td>958</td>
<td>0</td>
</tr>
<tr>
<td>Latvia</td>
<td>6</td>
<td>0</td>
<td>6</td>
<td>0</td>
</tr>
<tr>
<td>Lithuania</td>
<td>5</td>
<td>0</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>Luxembourg</td>
<td>58</td>
<td>0</td>
<td>58</td>
<td>0</td>
</tr>
<tr>
<td>Malta</td>
<td>34</td>
<td>0</td>
<td>34</td>
<td>0</td>
</tr>
<tr>
<td>Netherlands (Kingdom of the)</td>
<td>1266</td>
<td>0</td>
<td>1266</td>
<td>0</td>
</tr>
<tr>
<td>Norway</td>
<td>96</td>
<td>0</td>
<td>96</td>
<td>0</td>
</tr>
<tr>
<td>Poland</td>
<td>189</td>
<td>28</td>
<td>217</td>
<td>0</td>
</tr>
<tr>
<td>Portugal</td>
<td>1004</td>
<td>1</td>
<td>1005</td>
<td>1</td>
</tr>
<tr>
<td>Republic of Moldova</td>
<td>2</td>
<td>0</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Romania</td>
<td>47</td>
<td>0</td>
<td>47</td>
<td>0</td>
</tr>
<tr>
<td>San Marino</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Serbia</td>
<td>40</td>
<td>0</td>
<td>40</td>
<td>0</td>
</tr>
<tr>
<td>Slovakia</td>
<td>14</td>
<td>0</td>
<td>14</td>
<td>0</td>
</tr>
<tr>
<td>Slovenia</td>
<td>47</td>
<td>0</td>
<td>47</td>
<td>0</td>
</tr>
<tr>
<td>Spain</td>
<td>7563</td>
<td>2</td>
<td>7565</td>
<td>3</td>
</tr>
<tr>
<td>Sweden</td>
<td>260</td>
<td>0</td>
<td>260</td>
<td>0</td>
</tr>
<tr>
<td>Switzerland</td>
<td>554</td>
<td>0</td>
<td>554</td>
<td>0</td>
</tr>
<tr>
<td>Türkiye</td>
<td>12</td>
<td>0</td>
<td>12</td>
<td>0</td>
</tr>
<tr>
<td>Ukraine</td>
<td>5</td>
<td>0</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>3574</td>
<td>148</td>
<td>3722</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td>25714</td>
<td>179</td>
<td>25893</td>
<td>7</td>
</tr>
</tbody>
</table>
**DEMOGRAPHICS**

**Figure 7: Age and gender distribution of cases of mpox, European Region, TESSy, 2022–2023**

Gender from 14 cases is reported as Other and these cases are not depicted on this graph. Information on gender is missing for 49 cases and information on age is missing for 32 cases.

Data on gender is collected as Female, Male, Other (e.g., transgender man, transgender woman and collected as free text), or Unknown.
The median time between symptom onset and diagnosis was 7 days.

**Figure 8: Distribution of symptoms among those reporting at least one type of symptom (N=16140), European Region, TESSy, 2022–2023**

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Number of Cases</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any type of rash</td>
<td>15415 (95.5%)</td>
<td></td>
</tr>
<tr>
<td>Systemic symptoms*</td>
<td>10968 (68%)</td>
<td></td>
</tr>
<tr>
<td>Skin/mucosal lesions (excl. oral or anogenital areas)</td>
<td>8158 (50.5%)</td>
<td></td>
</tr>
<tr>
<td>Anogenital dermatological lesions</td>
<td>7905 (49%)</td>
<td></td>
</tr>
<tr>
<td>Localized lymphadenopathy</td>
<td>5255 (32.6%)</td>
<td></td>
</tr>
<tr>
<td>Rash, unknown location</td>
<td>3373 (20.9%)</td>
<td></td>
</tr>
<tr>
<td>Sore throat</td>
<td>1835 (11.4%)</td>
<td></td>
</tr>
<tr>
<td>Oral dermatological lesions</td>
<td>1766 (10.9%)</td>
<td></td>
</tr>
<tr>
<td>Lymphadenopathy, location unknown</td>
<td>1579 (9.8%)</td>
<td></td>
</tr>
<tr>
<td>Generalized lymphadenopathy</td>
<td>622 (3.9%)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>398 (2.5%)</td>
<td></td>
</tr>
<tr>
<td>Anal/rectal pain and/or rectal bleeding and/or proctitis</td>
<td>321 (2%)</td>
<td></td>
</tr>
<tr>
<td>Respiratory symptoms</td>
<td>257 (1.6%)</td>
<td></td>
</tr>
<tr>
<td>Vomiting or nausea</td>
<td>123 (0.8%)</td>
<td></td>
</tr>
<tr>
<td>Conjunctivitis</td>
<td>41 (0.3%)</td>
<td></td>
</tr>
<tr>
<td>Asymptomatic</td>
<td>11 (0.1%)</td>
<td></td>
</tr>
<tr>
<td>Sensitivity to light</td>
<td>10 (0.1%)</td>
<td></td>
</tr>
</tbody>
</table>
Table 3: Distribution of rash and systemic symptoms among those reporting at least one type of symptom (N=16140), European Region, TESSy, 2022–2023

<table>
<thead>
<tr>
<th>Any type of rash</th>
<th>Systemic Symptoms*</th>
<th>Count (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Absent</td>
<td>Absent</td>
<td>142 (0.9%)</td>
</tr>
<tr>
<td>Absent</td>
<td>Present</td>
<td>583 (3.6%)</td>
</tr>
<tr>
<td>Present</td>
<td>Absent</td>
<td>5,030 (31.2%)</td>
</tr>
<tr>
<td>Present</td>
<td>Present</td>
<td>10,385 (64.3%)</td>
</tr>
<tr>
<td>Total</td>
<td>-</td>
<td>16,140 (100%)</td>
</tr>
</tbody>
</table>

*Fever, fatigue, muscle pain, chills, headache

Detection of asymptomatic cases is dependent on testing guidelines which currently do not recommend testing asymptomatic persons
## OUTCOME, HIV STATUS

**Table 4: Summary of outcome and HIV status of cases, European Region, TESSy, 2022–2023**

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Yes</th>
<th>No</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Admitted to ICU</td>
<td>8 (0.1%)</td>
<td>7,053 (99.9%)</td>
<td>7,061 (100%)</td>
</tr>
<tr>
<td>Hospitalized*</td>
<td>825 (6.7%)</td>
<td>11,543 (93.3%)</td>
<td>12,368 (100%)</td>
</tr>
<tr>
<td>Died</td>
<td>7 (0.0%)</td>
<td>18,085 (100%)</td>
<td>18,092 (100%)</td>
</tr>
<tr>
<td>HIV-Positive</td>
<td>4,076 (38.0%)</td>
<td>6,653 (62.0%)</td>
<td>10,729 (100%)</td>
</tr>
</tbody>
</table>

*Includes cases hospitalized for isolation or treatment (189 cases were hospitalized for isolation purposes, 277 required clinical care and 359 were hospitalized for unknown reasons).
SEXUAL ORIENTATION

Sexual orientation in TESSy is defined according to the following non-mutually exclusive categories:

- Heterosexual
- MSM = MSM/homo or bisexual male
- Women who have sex with women
- Bisexual
- Other
- Unknown or undetermined

Sexual orientation is not necessarily representative of the gender of the person the case had sex with in the past 21 days nor does it imply sexual contact and sexual transmission.

We summarize here the sexual orientation that male cases identified with.

Table 5: Summary of reported sexual orientations among male cases of mpox, European Region, TESSy, 2022–2023

<table>
<thead>
<tr>
<th>Sexual Orientation</th>
<th>Count (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MSM</td>
<td>10,846 (42.7%)</td>
</tr>
<tr>
<td>Bisexual</td>
<td>132 (0.5%)</td>
</tr>
<tr>
<td>Heterosexual</td>
<td>337 (1.3%)</td>
</tr>
<tr>
<td>Unknown or undetermined</td>
<td>2,809 (11.1%)</td>
</tr>
<tr>
<td>Not reported</td>
<td>11,272 (44.4%)</td>
</tr>
<tr>
<td>Total</td>
<td>25,396 (100%)</td>
</tr>
</tbody>
</table>
### MICROBIOLOGICAL ANALYSES

#### SPECIMEN TYPES

Table 6: Summary of specimen types with positive test result used for diagnosis of mpox, European Region, TESSy, 2022–2023

<table>
<thead>
<tr>
<th>Specimen type</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lesion swab</td>
<td>5,444 (59.0%)</td>
</tr>
<tr>
<td>Lesion crust</td>
<td>2,841 (30.8%)</td>
</tr>
<tr>
<td>Oropharyngeal swab</td>
<td>582 (6.3%)</td>
</tr>
<tr>
<td>Rectal swab</td>
<td>223 (2.4%)</td>
</tr>
<tr>
<td>Genital swab</td>
<td>98 (1.1%)</td>
</tr>
<tr>
<td>Urine</td>
<td>21 (0.2%)</td>
</tr>
<tr>
<td>Serum</td>
<td>14 (0.2%)</td>
</tr>
<tr>
<td>Semen</td>
<td>0 (0.0%)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>9,223 (100%)</strong></td>
</tr>
</tbody>
</table>
PHYLOGENETICS

Phylogenetics of mpopx virus

Phylogeny of human monkeypox virus was performed using Nextstrain. Briefly, genome sequences were extracted from Nextstrain repository comprising the curated NCBI GenBank sequences and metadata that were quality assessed using Nextclade. The sequences were filtered for the Nextstrain curated exclusions, minimum length of 10000 bp, collected from 2017 and subsampling of 40 samples per country during the same sampling month and year. The phylogenetic analysis was performed using Nextalign (masking specific sites), IQTREE to construct the tree and TreeTime to refine the tree and visualized using Microreact.

There are two genetically distinct clades described for monkeypox virus: Clade I and Clade II with sub-clades IIa and IIb. The current outbreak falls within Clade IIb and following the nomenclature used in Nextstrain, a majority of the 2022 sequences belong to lineage B.1. A few sequences do not cluster with the outbreak sequences but fall into lineages A.2 and A.3. Figure A shows a phylogeny based on sequences from Clade IIb. The phylogeny is also visualized in Microreact along with the sequence metadata. Sequences from 2022 and 2023 are indicated with coloured circles and the binary heatmap shows sequences submitted after 16 January 2023.

Figure A. Phylogenetic tree of monkeypox virus sequences of Clade IIb as of 30 January 2023.


5. Nextstrain Genomic epidemiology of monkeypox virus. Available at: https://nextstrain.org/monkeypox/hmpxv1


DISCLAIMERS AND ACKNOWLEDGMENTS

COPYRIGHT STATEMENT AND DISCLAIMERS

Users are advised to interpret all data with caution and be aware of their limitations. Case counts and their corresponding data may have weekly updates that include historical corrections as new information is collected and reported.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO or ECDC concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.

The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO or ECDC in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO and ECDC to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO or ECDC be liable for damages arising from its use.

Copyright, permissions and referencing:

The WHO Regional Office for Europe is responsible for the accuracy of the Russian translation.


Tables and figures should be referenced: European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Mpox, Joint Epidemiological overview, 11 August 2023.

© European Centre for Disease Prevention and Control 2023.

Some rights reserved. This work is available under the Creative Commons Attribution-4.0 International (CC BY-4.0; Creative Commons — Attribution 4.0 International — CC BY 4.0). In any use of this work, there should be no suggestion that WHO or ECDC endorse any specific organization, products or services. The use of the ECDC or WHO logo is not permitted. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the European Centre for Disease Prevention and Control (ECDC) or by the World Health Organization (WHO). ECDC and WHO are not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition.”
ACKNOWLEDGMENTS

We gratefully acknowledge the Nextstrain team, the authors, originating and submitting laboratories of the genetic sequences and metadata (NCBI Genbank) for sharing their work.
**ANNEX**

**WHO and ECDC case definition prior to 22/12/2022**

Cases of monkeypox should be reported to TESSy if they meet any of the WHO, ECDC or national case definitions.

**Confirmed case**

- Laboratory confirmed monkeypox virus infection by detection of unique sequences of viral DNA by real-time polymerase chain reaction (PCR)\(^1\) and/or sequencing.

**Probable case:**

- A person presenting with an unexplained acute skin rash, mucosal lesions or lymphadenopathy (swollen lymph nodes). The skin rash may include single or multiple lesions in the ano-genital region or elsewhere on the body. Mucosal lesions may include single or multiple oral, conjunctival, urethral, penile, vaginal, or ano-rectal lesions. Anorectal lesions can also manifest as ano-rectal inflammation (proctitis), pain and/or bleeding.

**AND One or more of the following:**

- has an epidemiological link\(^2\) to a probable or confirmed case of monkeypox in the 21 days before symptom onset;
- identifies as gay, bisexual or other man who has sex with men;
- has had multiple or anonymous sexual partners in the 21 days before symptom onset;
- has detectable levels of anti-orthopoxvirus (OPXV) IgM antibody\(^3\) (during the period of 4 to 56 days after rash onset); or a four-fold rise in IgG antibody titre based on acute (up to day 5-7) and convalescent (day 21 onwards) samples; in the absence of a recent smallpox/monkeypox vaccination or other known exposure to OPXV; *has a positive test result for orthopoxviral infection (e.g. OPXV-specific PCR without MPXV-specific PCR or sequencing)\(^1\).

**Suspected case**

- A person who is a contact of a probable or confirmed monkeypox case in the 21 days before the onset of signs or symptoms, and who presents with any of the following: acute onset of fever (>38.5°C), headache, myalgia (muscle pain/body aches), back pain, profound weakness or fatigue.
OR

• A person presenting since 01 January 2022 with an unexplained acute skin rash, mucosal lesions or lymphadenopathy (swollen lymph nodes). The skin rash may include single or multiple lesions in the ano-genital region or elsewhere on the body. Mucosal lesions may include single or multiple oral, conjunctival, urethral, penile, vaginal, or ano-rectal lesions. Ano-rectal lesions can also manifest as ano-rectal inflammation (proctitis), pain and/or bleeding.

AND for which the following common causes of acute rash or skin lesions do not fully explain the clinical picture:

• varicella zoster, herpes zoster, measles, herpes simplex, bacterial skin infections, disseminated gonococcus infection, primary or secondary syphilis, chancroid, lymphogranuloma venereum, granuloma inguinale, molluscum contagiosum, allergic reaction (e.g., to plants); and any other locally relevant common causes of papular or vesicular rash.

N.B. It is not necessary to obtain negative laboratory results for listed common causes of rash illness in order to classify a case as suspected. Further, if suspicion of monkeypox infection is high due to either history and/or clinical presentation or possible exposure to a case, the identification of an alternate pathogen which causes rash illness should not preclude testing for MPXV, as coinfections have been identified.

Discarded case

• A suspected or probable case for which laboratory testing of lesion fluid, skin specimens or crusts by PCR and/or sequencing is negative for MPXV1.
• Conversely, a retrospectively detected probable case for which lesion testing can no longer be adequately performed (i.e., after the crusts fall off) and no other specimen is found PCR-positive, would remain classified as a probable case.
• A suspected or probable case should not be discarded based on a negative result from an oropharyngeal, anal or rectal swab.

Both the previous WHO and ECDC case definitions can be found in the Annex.

1. PCR on a blood specimen may be unreliable and should also not be used alone as a first line diagnostic test. If blood PCR is negative and was the only test done, this is not sufficient to discard a case that otherwise meets the definition of a suspected for probable case. This applies regardless of whether the blood PCR was for OPXV or MPXV specific.
2. The person has been exposed to a probable or confirmed monkeypox case. Please see below definition of a contact.

3. Serology can be used for retrospective case classification for a probable case in specific circumstances such as when diagnostic testing through PCR of skin lesion specimens has not been possible, or in the context of research with standardized data collection. The primary diagnostic test for monkeypox diagnosis is PCR of skin lesion material or other specimen such as an oral or nasopharyngeal swab as appropriate. Serology should not be used as a first line diagnostic test.

**ECDC case definition for monkeypox prior to 08/09/2022**:

**Confirmed case**:

- A person with a laboratory-confirmed monkeypox infection (1) monkeypox virus specific PCR assay positive result or (2) orthopoxvirus-specific PCR assay positive result which is then confirmed by nucleotide sequence determination of the detected virus as MPXV) with symptom onset since 1 March 2022.

**Probable case**:

(1) A person with an unexplained rash\(^1\) on any part of their body AND one or more other symptom(s) of monkeypox infection\(^2\) with symptom onset since 1 March 2022

**AND one of the following**:

- has a positive laboratory test result on orthopoxviral infection (e.g., orthopoxvirus-specific positive PCR without sequencing, electron microscopy, serology);
- has an epidemiological link to a confirmed or probable case of monkeypox in the 21 days before symptom onset;
- reports travel to MPX endemic countries in the 21 days before symptom onset;
- is a person (of any sexual orientation) who had multiple or anonymous sexual partners in the 21 days before symptom onset;
- is a man who has sex with men.

**OR**

(2) A person with an unexplained generalized or localized maculopapular or vesiculopustular rash with centrifugal spread, with lesions showing umbilication or scabbing, lymphadenopathy and one or more other MPX-compatible symptoms\(^2\).
1. Since EU/EEA countries are just starting to identify cases and if testing capacity is sufficient, the above more sensitive case definition can be used. In countries with limited testing capacity for orthopoxviruses, the following description can be added to characterize the rash: ‘unexplained localized or generalized maculopapular or vesiculopustular rash potentially with umbilication or scabbing’.

2. Fever (usually higher >38.5°C), headache, back ache, fatigue, lymphadenopathy (localized or generalized).

WHO case definition for monkeypox prior to 25/08/2022:

**Confirmed case**

- Laboratory confirmed monkeypox virus by detection of unique sequences of viral DNA by real-time polymerase chain reaction (PCR)\(^1\) and/or sequencing.

**Probable case:**

- A person meeting the case definition for a suspected case

**AND One or more of the following:**

- has an epidemiological link [prolonged\(^2\) face-to-face exposure in close proximity, including health workers without appropriate PPE (gloves, gown, eye protection and respirator); direct physical contact with skin or skin lesions, including sexual contact; or contact with contaminated materials such as clothing, bedding or utensils] to a probable or confirmed case of monkeypox in the 21 days before symptom onset;
- has had multiple or anonymous sexual partners in the 21 days before symptom onset;
- has detectable levels of anti-orthopoxvirus (OPXV) IgM antibody\(^3\) (during the period of 4 to 56 days after rash onset); or a four-fold rise in IgG antibody titre based on acute (up to day 5-7) and convalescent (day 21 onwards) samples; in the absence of a recent smallpox/monkeypox vaccination or other known exposure to OPXV;
- has a positive test result for orthopoxviral infection (e.g. OPXV-specific PCR without MPXV-specific PCR or sequencing)\(^1\).
Suspected case

- A person of any age presenting since 01 January 2022 with an unexplained acute rash or one or more acute skin lesions

AND one or more of the following signs or symptoms:

- headache, acute onset of fever (≥38.5°C), lymphadenopathy (swollen lymph nodes), myalgia (muscle pain/body aches), back pain, asthenia (profound weakness)

AND for which the following common causes of acute rash or skin lesions do not fully explain the clinical picture:

- varicella zoster, herpes zoster, measles, herpes simplex, bacterial skin infections, disseminated gonococcus infection, primary or secondary syphilis, chancroid, lymphogranuloma venereum, granuloma inguinale, molluscum contagiosum, allergic reaction (e.g., to plants); and any other locally relevant common causes of papular or vesicular rash.

N.B. It is not necessary to obtain negative laboratory results for listed common causes of rash illness in order to classify a case as suspected. Further, if suspicion of monkeypox infection is high due to either history and/or clinical presentation or possible exposure to a case, the identification of an alternate pathogen which causes rash illness should not preclude testing for MPXV, as coinfections have been identified.

Discarded case

- A suspected or probable case for which laboratory testing of lesion fluid, skin specimens or crusts by PCR and/or sequencing is negative for MPXV¹.
- Conversely, a retrospectively detected probable case for which lesion testing can no longer be adequately performed (i.e., after the crusts fall off) and no other specimen is found PCR-positive, would remain classified as a probable case.

1. PCR on a blood specimen may be unreliable and should also not be used alone as a first line diagnostic test. If blood PCR is negative and was the only test done, this is not sufficient to discard a case that otherwise meets the definition of a suspected for probable case. This applies regardless of whether the blood PCR was for OPXV or MPXV specific.
2. Evidence is currently lacking as to the duration of exposure necessary for infection by the respiratory route, including how it relates to the severity of the index case’s disease. Characterization of this parameter is one of the goals of the case investigation form described below.

3. Serology can be used for retrospective case classification for a probable case in specific circumstances such as when diagnostic testing through PCR of skin lesion specimens has not been possible, or in the context of research with standardized data collection. The primary diagnostic test for monkeypox diagnosis is PCR of skin lesion material or other specimen such as an oral or nasopharyngeal swab as appropriate. Serology should not be used as a first line diagnostic test.